patient view
This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.
drug · antibody drug conjugate
patritumab deruxtecan
Phase 3updated 2mo agoby Daiichi Sankyo Co Ltd🔗 ChEMBL
Phase 3community read0 votes
Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 6 investigational indications.
indications
indications
NSCLC
targets
Receptor tyrosine-protein kinase erbB-3DNA topoisomerase 1
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that